Tebentafusp for Uveal Melanoma: Assessing Treatment Response

Source: OncLive, July 2021

Richard D. Carvajal, MD: You’re right, this is reminiscent to me of the ipilimumab experience where you get the survival benefit despite the low response rate. But even more so here, we’ve both had patients that we’ve treated where the radiographic disease course has been remarkable, right? Where it’s significant progression and then a flattening of the curve.

READ THE ORIGINAL FULL ARTICLE